Patient Updates From the 2025 ASH Annual Meeting: Leukemia (Part 3)
•February 6, 2026
0
Why It Matters
The venetoclax‑based low‑intensity regimen could shift frontline treatment paradigms for selected AML patients by improving event‑free survival and transplant eligibility with less toxicity, while CLN049 offers a novel immunotherapy option for refractory, high‑risk disease where effective treatments are scarce. These advances may increase curative transplant access and fill an urgent unmet need in TP53‑mutant AML.
Summary
At the 2025 ASH meeting presenters highlighted two key leukemia developments: a randomized phase II comparison showed lower‑intensity azacitidine plus venetoclax outperformed intensive 7+3 chemotherapy for event‑free survival and remission depth in a selected AML population, and more patients on the low‑intensity arm proceeded to transplant, although overall survival was similar. Separately, a phase I study of CLN049, a FLT3×CD3 bispecific engager, produced meaningful anti‑leukemic activity—including MRD‑negative complete remissions—in heavily pretreated, high‑risk AML/MDS patients (many with TP53 mutations), with generally manageable cytokine release and liver toxicities. Responses at the highest dose were durable and enabled transplant for some patients. Based on these results, CLN049 is moving forward with FDA fast‑track designation and expansion cohorts.
Original Description
Tune into a three-part webinar series that delivers the most important clinical and scientific breakthroughs presented at the latest American Society of Hematology (ASH) Annual Meeting in December 2025. Part 3 uncovers the latest findings in leukemia, including AML, ALL, MDS, and MPN, translating cutting-edge data into practical insights for patients and caregivers. Leading experts from Perlmutter Cancer Center’s Center for Blood Cancers and Blood Cancer United highlight clinical trial updates, emerging treatment strategies, and implications for disease management for patients in 2025 and beyond.
00:00 Opening Remarks
00:47 ASH Updates for Acute Myeloid Leukemia (AML)
10:48 ASH Updates for Acute Lymphoblastic Leukemia (ALL)
19:57 ASH Updates for Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasm (MPN)
29:26 Blood Cancer United Resources
36:31 Patient Story
43:02 Audience Questions & Answers
View slides
ASH Updates for AML: https://image.e.nyulangone.org/lib/fe3611717164067e731573/m/1/b7202d00-f1e3-4805-b136-6f10882cc8b9.pdf
ASH Updates for ALL: https://image.e.nyulangone.org/lib/fe3611717164067e731573/m/1/4bab9360-ddbb-4c6c-8dc4-bac45909f892.pdf
ASH Updates for MDS and MPN: https://image.e.nyulangone.org/lib/fe3611717164067e731573/m/1/e394fb6f-bd10-4ab0-bd99-21c328daa79e.pdf
Blood Cancer United Resources: https://image.e.nyulangone.org/lib/fe3611717164067e731573/m/1/39d5b277-a32e-4ae2-b67c-90cfe745b86b.pdf
Watch the entire Patient Updates from ASH 2025 series:
Learn about PCC’s Center for Blood Cancers: https://nyulangone.org/locations/center-for-blood-cancers
Learn about PCC’s Center for Blood Cancers Research: https://med.nyu.edu/departments-institutes/perlmutter-cancer-center/cancer-research/cancer-disease-management-groups-centers/hematologic-malignancies-research/center-blood-cancers-research
Learn more about Dr. Mohammad Maher Abdul Hay: https://nyulangone.org/doctors/1447494729/mohammad-maher-abdul-hay
Learn more about Dr. Dimitrios Papaioannou: https://nyulangone.org/doctors/1083119747/dimitrios-papaioannou
- - -
To register for free upcoming events from NYU Langone’s Perlmutter Cancer Center, subscribe to our monthly community email newsletter: https://connect.nyulangone.org/email-preferences/sign-up?campaign=pcc_campaign
0
Comments
Want to join the conversation?
Loading comments...